CKD-501, D744, D150

DRUG2 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

Type 2 Diabetes

Phase 1

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

CompletedNCT05816759

Chong Kun Dang PharmaceuticalType 2 Diabetes

Start: 2023-05-26End: 2023-06-22Updated: 2024-01-23

Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers

CompletedNCT07304700

Chong Kun Dang PharmaceuticalType 2 Diabetes

Start: 2025-10-28End: 2025-11-12Updated: 2025-12-26